Inclusion Criteria:

- Diagnosis of melanoma, AJCC stage IIB, IIC, III, or IV (MIa), with histologic
confirmation by the Department of Pathology at MSKCC.

- Patients must be HLA-A*0201 positive, based on high resolution DNA level typing.

- Expected survival of greater than 3 months.

- Karnofsky performance status of 70 or higher

- All patients should have undergone surgical treatment appropriate to their stage of
disease

- Patients may not have received chemotherapy, immunotherapy, or radiation within a
minimum of 28 days (minimum of 42 days for nitrosoureas or mitomycin) before
participation in this protocol.

Exclusion Criteria:

- Pregnant or lactating women because of unknown risks to the fetus or infant.

- Patients requiring systemic corticosteroids or comparable exogenous immunosuppressive
agent(s) (no exclusion for use of NSAIDs).

- Patients with a known immunodeficiency (e.g., infection with HTLV-1,2, HIV-1,2;
etc.).

- Patients with coexisting autoimmune diseases, except vitiligo.

- Patients with baseline impairments of hematologic, hepatic, or renal function (CTCAE
v4.0 > grade 1, ANC < 1500, hgb < 10.0 g/dl, plts < 75,000/ul, AST > 3x ULN,
creatinine > 1.5xULN), all assessed within four weeks of study entry.

- Patients with organ allografts.

- Patients who are status post splenectomy or status post splenic irradiation.

- Patients with a history of documented pre-existing retinal/choroidal disease.